Monocytes and macrophages in CAR T-cell-associated hematotoxicity: mechanisms linking inflammatory amplification to hematopoietic suppression and opportunities for clinical translation
Abstract
Immune effector cell-associated hematotoxicity (ICAHT) is a clinically important complication of chimeric antigen receptor (CAR) T-cell therapy. It may present as early, prolonged, or late-onset neutropenia, anemia, and thrombocytopenia, and cannot be fully explained by lymphodepleting chemotherapy or treatment-related depletion of bone marrow reserve. A growing body of clinical and experimental evidence suggests that post-infusion hyperinflammation impairs hematopoietic recovery. Monocytes and macrophages may form a critical cellular link between T-cell activation, inflammatory amplification, and hematopoietic suppression. Monocytes and macrophages amplify CAR T-cell-associated cytokine release syndrome (CRS), but their contribution to persistent ICAHT is less clearly defined. Distinguishing acute inflammatory amplification from sustained disruption of marrow function is essential for interpreting the available evidence. This review examines myeloid-cell activation and functional reprogramming after CAR T-cell therapy, with particular emphasis on how myeloid inflammation may contribute to ICAHT by directly impairing hematopoietic stem and progenitor cells, disrupting the bone marrow microenvironment, and perturbing granulopoiesis and erythropoiesis. We also assess the translational potential of myeloid-associated biomarkers and inflammation-directed therapies and identify questions that require longitudinal sampling of peripheral blood and bone marrow, multi-omics analyses, and functional validation.
Related
- CAR-ENGINEERED HUMAN HEMATOPOIETIC STEM CELL MACROPHAGES AS AN INNOVATIVE PLATFORM FOR TUMOR CONTROL
- Identification and characterization of inflammatory LILR and fibrotic SPP1 macrophages in chronic lung allograft dysfunction
- Extract-equivalent decursin and decursinol angelate reproduce major anti-inflammatory effects of Angelica gigas root ethanol extract in LPS-stimulated macrophages
- Aryl hydrocarbon receptor (AhR) restrains the maintenance and acquisition of the anti-inflammatory identity of monocyte-derived macrophages.
- Low-molecular-weight Ulva lacinulata extract exhibiting anti-inflammatory and pro-autophagic activities in RAW 264.7 macrophages: a promising candidate for the development of active ingredients targeting low-grade inflammation
BibTeX
@article{wang2026monocytes,
title = {{Monocytes and macrophages in CAR T-cell-associated hematotoxicity: mechanisms linking inflammatory amplification to hematopoietic suppression and opportunities for clinical translation}},
author = {Zining Wang and Yu Gao and Chunyan Liu and Rong Fu},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2003955},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2003955},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Monocytes and macrophages in CAR T-cell-associated hematotoxicity: mechanisms linking inflammatory amplification to hematopoietic suppression and opportunities for clinical translation
AU - Zining Wang
AU - Yu Gao
AU - Chunyan Liu
AU - Rong Fu
PY - 2026
DA - 2026/11/11
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2003955
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2003955
AB - Immune effector cell-associated hematotoxicity (ICAHT) is a clinically important complication of chimeric antigen receptor (CAR) T-cell therapy. It may present as early, prolonged, or late-onset neutropenia, anemia, and thrombocytopenia, and cannot be fully explained by lymphodepleting chemotherapy or treatment-related depletion of bone marrow reserve. A growing body of clinical and experimental evidence suggests that post-infusion hyperinflammation impairs hematopoietic recovery. Monocytes and macrophages may form a critical cellular link between T-cell activation, inflammatory amplification, and hematopoietic suppression. Monocytes and macrophages amplify CAR T-cell-associated cytokine release syndrome (CRS), but their contribution to persistent ICAHT is less clearly defined. Distinguishing acute inflammatory amplification from sustained disruption of marrow function is essential for interpreting the available evidence. This review examines myeloid-cell activation and functional reprogramming after CAR T-cell therapy, with particular emphasis on how myeloid inflammation may contribute to ICAHT by directly impairing hematopoietic stem and progenitor cells, disrupting the bone marrow microenvironment, and perturbing granulopoiesis and erythropoiesis. We also assess the translational potential of myeloid-associated biomarkers and inflammation-directed therapies and identify questions that require longitudinal sampling of peripheral blood and bone marrow, multi-omics analyses, and functional validation.
SN - 1664-3224
ER -